Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) Equity Ratio (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Equity Ratio for 16 consecutive years, with 0.27 as the latest value for Q3 2025.

  • On a quarterly basis, Equity Ratio rose 136.51% to 0.27 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.27, a 136.51% increase, with the full-year FY2024 number at 1.35, down 1039.78% from a year prior.
  • Equity Ratio was 0.27 for Q3 2025 at Plus Therapeutics, down from 0.29 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.6 in Q1 2022 to a low of 1.96 in Q1 2025.
  • A 5-year average of 0.06 and a median of 0.23 in 2023 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: surged 12697.65% in 2021, then tumbled 1039.78% in 2024.
  • Plus Therapeutics' Equity Ratio stood at 0.6 in 2021, then tumbled by 54.7% to 0.27 in 2022, then crashed by 143.83% to 0.12 in 2023, then plummeted by 1039.78% to 1.35 in 2024, then skyrocketed by 120.06% to 0.27 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Equity Ratio are 0.27 (Q3 2025), 0.29 (Q2 2025), and 1.96 (Q1 2025).